Expression of genes for estrogen receptors α and β in human articular chondrocytes

AbstractObjective To investigate the gene expression of estrogen receptor (ER) α and ERβ in human articular chondrocytes.Methods 16 articular cartilage specimens were obtained from 15 patients during surgery. Three of the specimens were from men and 13 from women; three from hip joints and 13 from knee joints; four were normal and 12 showed osteoarthritic cartilage. Total RNA was extracted from the articular chondrocytes and the expression of both ERα and ERβ genes was investigated by the reverse transcription-polymerase chain reaction (RT-PCR) method.Results Gene expressions of ERα were detected in all specimens and those of ERβ were found in 15 specimens by the RT-PCR method. There was a significant correlation between the amounts of ERα and ERβ. Expression levels of both genes were significantly higher in men than in women. There were no significant differences in the expression levels of both ER genes between the hip and knee joint sites, nor between normal and osteoarthritic tissues.Conclusion This study is to our knowledge the first to demonstrate the gene expression of both ERα and ERβ in human articular chondrocytes. Since there are some functional differences between the two receptors, the effects of estrogen on cartilage metabolism should be elucidated by two different receptor mechanisms.{copy

Lidocaine for systemic sclerosis: a double-blind randomized clinical trial

Background: Systemic sclerosis (scleroderma; SSc) is an orphan disease with the highest case-specific mortality of any connective-tissue disease. Excessive collagen deposit in affected tissues is a key for the disease's pathogenesis and comprises most of the clinical manifestations. Lidocaine seems to be an alternative treatment for scleroderma considering that: a) the patient's having excessive collagen deposits in tissues affected by scleroderma; b) the patient's demonstrating increased activity of the enzyme prolyl hydroxylase, an essential enzyme for the biosynthesis of collagen; and c) lidocaine's reducing the activity of prolyl hydroxylase. the aim of this study was to evaluate the efficacy and safety of lidocaine in treating scleroderma.Methods: A randomized double-blind clinical trial included 24 patients with scleroderma randomized to receive lidocaine or placebo intravenously in three cycles of ten days each, with a one-month interval between them. Outcomes: cutaneous (modified Rodnan skin score), oesophageal (manometry) and microvascular improvement (nailfold capillaroscopy); improvement in subjective self-assessment and in quality of life (HAQ).Results: There was no statistically significant difference between the groups for any outcome after the treatment and after 6-months follow-up. Improvement in modified Rodnan skin score occurred in 66.7% and 50% of placebo and lidocaine group, respectively (p = 0.408). Both groups showed an improvement in subjective self-assessment, with no difference between them.Conclusions: Despite the findings of a previous cohort study favouring the use of lidocaine, this study demonstrated that lidocaine at this dosage and means of administration showed a lack of efficacy for treating scleroderma despite the absence of significant adverse effects. However, further similar clinical trials are needed to evaluate the efficacy of lidocaine when administered in different dosages and by other means.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Universidade Federal de São Paulo, Escola Paulista Med UNIFESP EPM, Brazilian Cochrane Ctr, São Paulo, BrazilUniversidade Federal de São Paulo, Escola Paulista Med UNIFESP EPM, Discipline Emergency Med & Evidence Based Med, São Paulo, BrazilUniversidade Federal de São Paulo, Escola Paulista Med UNIFESP EPM, Discipline Rheumatol, São Paulo, BrazilUniv Santo Amaro, Discipline Rheumatol, São Paulo, BrazilUniversidade Federal de São Paulo, Escola Paulista Med UNIFESP EPM, Brazilian Cochrane Ctr, São Paulo, BrazilUniversidade Federal de São Paulo, Escola Paulista Med UNIFESP EPM, Discipline Emergency Med & Evidence Based Med, São Paulo, BrazilUniversidade Federal de São Paulo, Escola Paulista Med UNIFESP EPM, Discipline Rheumatol, São Paulo, BrazilFAPESP: 01-13895-9Web of Scienc

Focal Spot, Summer/Fall 2005

https://digitalcommons.wustl.edu/focal_spot_archives/1100/thumbnail.jp

Focal Spot, Summer/Fall 2005

https://digitalcommons.wustl.edu/focal_spot_archives/1100/thumbnail.jp

Duality nature of Selective Androgen Receptor Modulators and Specific Steroids Substance

Selective Androgen Receptor Modulators (SARMs) are the novel class of the androgen receptors (AR), often called tissue-selective AR ligands. Discovery of SARMs will give a possibility to the alternative therapy for androgens therapy (osteoporosis, prostate cancer, muscle wasting). SARMs should have high specificity for the AR, tissue-selective pharmacokinetic activities, improved oral bioavailability and pharmacokinetic profile which allows once-a-day administration [1]. Example of SARMs is flutamide (flutamidum, Eulexin, imid 2-methyl-N-{4-nitro-(3-trifluoromethyl)-phenyl]- propionic acid), a synthetic nonsteroidal drug that is a competitive antagonist of the androgen receptor. SARMs were recognized as forbidden substances by the World Anti-Doping Agency (WADA) and since 2004 they are on the Prohibited List. To point on the Prohibited List 2019 “Substance and methods prohibited at all time (in- and out-of-competition)” SARMs belong to group S1. 2. Other Anabolic Agents, and to group S4. Hormone Antagonist and Modulators [2]. The main role of an anti-doping laboratory is to analyse and to determine whether a given substance should be prohibited in sport. The principal analyses of SARMs and Specific Steroid Substance are a different variant of chromatography (LC — liquid or GC — gas) with many detection techniques (MS — mainly mass spectrometer, MS/MS — tandem mass spectrometer)

Postnatal maternal separation affects hippocampal longterm potentiation in adult stressed rats : molecular and hormonal mechanisms

Magdeburg, Univ., Fak. für Naturwiss., Diss., 2013von Han Wan